BMS-955176: Difference between revisions
→Studies: shortened |
m Moving from Category:Experimental drugs to Category:Experimental antiviral drugs using Cat-a-lot |
||
(One intermediate revision by one other user not shown) | |||
Line 57: | Line 57: | ||
__TOC__ |
__TOC__ |
||
== Studies == |
== Studies == |
||
Results of a [[Clinical trial|phase 2a]] trial of BMS-955176 was reported at the 2015 [[Conference on Retroviruses and Opportunistic Infections]] (CROI).<ref name=":0">{{Cite web|title = Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor {{!}} CROI Conference|url = http://www.croiconference.org/sessions/antiviral-activitysafety-second-generation-hiv-1-maturation-inhibitor|website = www.croiconference.org|access-date = 2016-01-01}}</ref> Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.<ref name=":0" /><ref>{{Cite web|title = HIV maturation inhibitor BMS-955176 looks promising in early study|url = http://www.aidsmap.com/HIV-maturation-inhibitor-BMS-955176-looks-promising-in-early-study/page/2948854/|website = www.aidsmap.com|access-date = 2016-01-01}}</ref> |
Results of a [[Clinical trial|phase 2a]] trial of BMS-955176 was reported at the 2015 [[Conference on Retroviruses and Opportunistic Infections]] (CROI).<ref name=":0">{{Cite web|title = Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor {{!}} CROI Conference|url = http://www.croiconference.org/sessions/antiviral-activitysafety-second-generation-hiv-1-maturation-inhibitor|website = www.croiconference.org|access-date = 2016-01-01}}</ref> Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.<ref name=":0" /><ref>{{Cite web|title = HIV maturation inhibitor BMS-955176 looks promising in early study|url = http://www.aidsmap.com/HIV-maturation-inhibitor-BMS-955176-looks-promising-in-early-study/page/2948854/|website = www.aidsmap.com|access-date = 2016-01-01}}</ref> |
||
It appears that development of BMS-955176 has been terminated.<ref>{{cite web|url=http://www.thebodypro.com/content/78689/gsk-discontinues-development-of-maturation-inhibit.html|title=GSK Discontinues Development of Maturation Inhibitor BMS-955176}}</ref> |
It appears that development of BMS-955176 has been terminated.<ref>{{cite web|url=http://www.thebodypro.com/content/78689/gsk-discontinues-development-of-maturation-inhibit.html|title=GSK Discontinues Development of Maturation Inhibitor BMS-955176}}</ref> |
||
Line 71: | Line 71: | ||
[[Category:Antiretroviral drugs]] |
[[Category:Antiretroviral drugs]] |
||
[[Category:Maturation inhibitors]] |
[[Category:Maturation inhibitors]] |
||
[[Category:Experimental drugs]] |
[[Category:Experimental antiviral drugs]] |
Latest revision as of 20:41, 1 December 2023
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C42H62N2O4S |
Molar mass | 691.03 g·mol−1 |
3D model (JSmol) | |
| |
|
BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.[1] First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been selected to better tolerate gag polymorphisms.[2][3]
Studies[edit]
Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).[4] Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.[4][5]
It appears that development of BMS-955176 has been terminated.[6]
See also[edit]
References[edit]
- ^ "BMS Maturation Inhibitor Is Potent Against HIV in Early Trial". 25 February 2015. Archived from the original on 23 July 2015. Retrieved 22 July 2015.
- ^ "CROI2015: New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat - Project Inform".
- ^ Wang D, Lu W, Li F (November 2015). "Pharmacological intervention of HIV-1 maturation". Acta Pharmaceutica Sinica B. 5 (6): 493–9. doi:10.1016/j.apsb.2015.05.004. PMC 4675807. PMID 26713265.
- ^ a b "Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor | CROI Conference". www.croiconference.org. Retrieved 2016-01-01.
- ^ "HIV maturation inhibitor BMS-955176 looks promising in early study". www.aidsmap.com. Retrieved 2016-01-01.
- ^ "GSK Discontinues Development of Maturation Inhibitor BMS-955176".